Taiwan Advance Bio-Pharmaceutical (ROCO:4186) ROCE %: 15.26% (As of Dec. 2025)


ROCO:4186 Taiwan Advance Bio-Pharmaceutical Inc ROCO:4186
52 GF Score
Price NT$10.00
GF Value NT$17.86
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Taiwan Advance Bio-Pharmaceutical ROCE %?

Taiwan Advance Bio-Pharmaceutical ROCO:4186 +1.42% 52 ROCE % is 15.26% as of Dec. 2025. GuruFocus rates ROCO:4186 with a GF Score™ of 52/100 and a GF Value™ of NT$17.86 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Taiwan Advance Bio-Pharmaceutical's annualized ROCE % for the quarter that ended in Dec. 2025 was 15.26%.

Taiwan Advance Bio-Pharmaceutical  (ROCO:4186) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Taiwan Advance Bio-Pharmaceutical ROCE % Related Terms

Taiwan Advance Bio-Pharmaceutical ROCE % Historical Data

* Premium members only.

The historical data trend for Taiwan Advance Bio-Pharmaceutical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical ROCE % Chart

Taiwan Advance Bio-Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.89 2.11 -0.91 6.91 7.38

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.57 -0.30 14.39 -0.34 15.26
ROCO:4186
52GF Score
Taiwan Advance Bio-Pharmaceutical Inc ROCO:4186
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Advance Bio-Pharmaceutical ROCE % Calculation

Taiwan Advance Bio-Pharmaceutical's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=33.677/( ( (676.424 - 238.88) + (746.739 - 272.228) )/ 2 )
=33.677/( (437.544+474.511)/ 2 )
=33.677/456.0275
=7.38 %

Taiwan Advance Bio-Pharmaceutical's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=68.812/( ( (692.33 - 264.784) + (746.739 - 272.228) )/ 2 )
=68.812/( ( 427.546 + 474.511 )/ 2 )
=68.812/451.0285
=15.26 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 15.26% mean?
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a ROCE % of 15.26% as of Dec. 2025.
Is Taiwan Advance Bio-Pharmaceutical's ROCE % too high?
Taiwan Advance Bio-Pharmaceutical's current ROCE % is 15.26%. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's ROCE % compare to VRTX and REGN?
Taiwan Advance Bio-Pharmaceutical's ROCE % of 15.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Taiwan Advance Bio-Pharmaceutical's current ROCE % is 15.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.86, compared to a current price of NT$10.00 — trading 44% below its estimated fair value. The current ROCE % is 15.26%. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current ROCE % is 15.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued. The current stock price of NT$10.00 is trading 44% below its estimated GF Value™ of NT$17.86. GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:4186:

  • ROCE %: 15.26%
  • GF Value™: NT$17.86 vs. price of NT$10.00 (44% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Advance Bio-Pharmaceutical Business Description

Address No. 363, Section 2, Fuxing South Road, 5th Floor, Daan District, New Taipei City, TWN, 22180
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
52GF Score

Get the complete analysis for ROCO:4186

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.00
Price
NT$17.86
GF Value